Samsung Biologics Reveals Strong Q3 2025 Financial Performance

Samsung Biologics, a prominent contract development and manufacturing organization based in Incheon, South Korea, reported robust financial results for the third quarter of fiscal year 2025. The company announced consolidated revenue of KRW 1,660.2 billion and an operating profit of KRW 728.8 billion, reflecting strong operational performance and increased project execution across its facilities.

CEO and President John Rim highlighted the company’s ongoing commitment to operational excellence. “Our third quarter results reflect the solid foundation we have built through operational excellence and disciplined execution,” Rim stated. He emphasized that the company continues to prioritize standardization and scalability under the ExellenSTM manufacturing framework, which aims to deliver speed, reliability, and predictable outcomes for its partners.

Financial Highlights and Business Developments

In this quarter, Samsung Biologics achieved standalone revenue of KRW 1,257.5 billion, driven by full-scale operations at its Plant 4 and consistent sales across all business units. The company has maintained its annual revenue growth guidance, bolstered by steady demand from clients and effective capacity utilization.

The company secured new manufacturing and development contracts with global pharmaceutical partners, elevating its cumulative contract volume to over USD 20 billion since its establishment. This achievement underscores Samsung Biologics’ strong performance and the trust it has garnered from clients across a variety of modalities.

An important strategic move is the planned spin-off to separate the CDMO business from its subsidiary, which is on track for completion in November 2025. This separation is expected to allow both entities to focus on their strategic objectives more clearly, enhancing client satisfaction and long-term competitiveness in the market.

Innovative Manufacturing Framework and ESG Initiatives

Samsung Biologics introduced ExellenSTM, its optimized manufacturing framework designed to enhance operational efficiency. This framework integrates standardized designs, equipment, and processes across all facilities, providing greater flexibility in securing supply and ensuring rapid market readiness.

During the third quarter, the company also made strides in its environmental, social, and governance (ESG) initiatives. A Product Carbon Footprint (PCF) measurement system was established to monitor emissions across operations and supply chains. As a participant in the Sustainable Markets Initiative’s Health Systems Task Force, Samsung Biologics is committed to achieving carbon neutrality and encouraging suppliers to adopt sustainable practices.

With strong client demand and consistent operational performance, Samsung Biologics is well-positioned to meet its annual growth targets. The company remains focused on reliability, innovation, and sustainable business practices, reinforcing its role as a trusted partner in advancing global healthcare.

Samsung Biologics, recognized as a leading CDMO, offers comprehensive services from late discovery to commercial manufacturing. With a biomanufacturing capacity of 784,000 liters across its five plants, the company employs advanced technologies to support various therapeutic modalities, including multispecific antibodies and mRNA therapeutics.

For more information about Samsung Biologics, visit their official website at https://samsungbiologics.com/.

Media Contact:
Claire Kim
Head of Marketing & Global Communications
[email protected]